This formulation can fully harness the apoptotic effect induced by CAPE on MM cells (RPMI8226), mediated by caspase-9, enhancing biocompatibility and significantly inhibiting the growth of MM cells in vitro [112]. This evidence concerns the gene CASP9 and Miyoshi myopathy.